Company plans to conduct Phase 3 trial of BXCL501 in the at-home setting for TRANQUILITY program to support potential sNDA for acute treatment of agitation associated with dementia due to probable Alzheimer’s disease
Potential market opportunity for BXCL501 to include acute treatment of agitation across full spectrum of Alzheimer’s-related dementia and agitation severity across all care settings
Based on FDA feedback, Company plans to conduct Phase 3 trial with 120 mcg (IGALMI™ approved dose) in the at-home setting for SERENITY III program for acute treatment of agitation in bipolar disorders or schizophrenia
Key financial terms agreed with
Conference call and webcast set for 8:00 a.m. ET today
“This is a time of tremendous progress and excitement for our company and stakeholders, especially as we report a clinical development path forward for our TRANQUILITY program,” said
Progress on Two Late-Stage Clinical Programs
TRANQUILITY:
Evaluating potential use of BXCL501 for acute treatment of agitation associated with Alzheimer’s dementia
- Received meeting minutes from
October 11, 2023 FDA meeting. - Company aligned with FDA’s recommendation to conduct additional Phase 3 trial of BXCL501 to evaluate safety and collect additional efficacy data in at-home setting.
- Planned study expected to enroll approximately 100 patients aged 65 years and older with mild, moderate, or severe dementia who will self-administer 60 mcg of BXCL501 or placebo whenever agitation episodes occur over a four-week period.
- The long term safety requirement for submission will be discussed with the FDA based on the observed frequency of agitation
- TRANQUILITY III trial is no longer required for potential sNDA submission; Company plans to explore potential separate clinical development program for chronic agitation.
SERENITY III:
Evaluating potential at-home use of BXCL501 for agitation associated with bipolar disorders or schizophrenia
- Completed meeting with FDA on
November 8, 2023 ; meeting minutes expected by the first half ofDecember 2023 . - Based on FDA feedback, Company plans to conduct a Phase 3 trial with 120 mcg (IGALMI™ approved dose) to evaluate safety in at-home setting.
- Since IGALMI’s launch, the Company estimates more than 10,000 treatments (120 mcg or 180 mcg dose) have been administered; pharmacovigilance monitoring has revealed no new or unexpected safety events in clinical settings.
- Since IGALMI’s launch, the Company estimates more than 10,000 treatments (120 mcg or 180 mcg dose) have been administered; pharmacovigilance monitoring has revealed no new or unexpected safety events in clinical settings.
Strategic Financing Update:
- Company entered into a binding term sheet to amend strategic financing agreements with
Oaktree Capital Management andQatar Investment Authority , subject to entry into definitive documentation. The term sheet provides for revised key financial terms that are expected to enhance the Company’s operational and financial flexibility, including:- Revised terms that would increase the Company’s potential to access additional tranches of capital under the agreements; and
- Revised revenue covenant to extend the deadline for compliance and adjust covenant levels to reflect current projections (this is intended to reduce short-term cash outflows that would be required to cure the revenue covenant if not satisfied).
- Company secured waiver and modification to covenant regarding investments in OnkosXcel Therapeutics.
IGALMI™ Commercialization
- Building brand awareness through contracting approach as Company prepares for potential larger at-home market opportunities, if approved in such indications.
- Permanent IGALMI J-Code issued from
Centers for Medicare & Medicaid Services expected to streamline reimbursement process across commercial and government payers. - Patent protection extended up to 2043 with two new Orange Book-listed
U.S. patents related to method of use of sublingual dexmedetomidine for treatment of agitation associated with bipolar disorders and schizophrenia.
OnkosXcel Therapeutics
- Reported positive overall survival results from open-label Phase 2 trial of BXCL701 in patients with metastatic castration-resistant prostate cancer of adenocarcinoma phenotype and in patients with small cell neuroendocrine prostate cancer.
- Focusing on strategic options for OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A.
Third Quarter 2023 Financial Results
Net Revenue: Net revenue of IGALMI was approximately
Research and Development (R&D) Expenses: R&D expenses were
Selling, General and Administrative (SG&A) Expenses: SG&A expenses were
Net Loss:
Cash and cash equivalents totaled
Conference Call and Webcast
automatically receive email alerts and other information about the Company by visiting the “Email Alerts” option under the News/Events section of the Investors & Media website section and submitting your email address.
About IGALMI™ (dexmedetomidine) sublingual film
INDICATION
IGALMI™ (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.
IMPORTANT SAFETY INFORMATION
IGALMI can cause serious side effects, including:
- Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint.
- Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations.
- Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI.
- Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours.
The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing.
These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects.
Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids.
Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact
Please see full Prescribing Information at igalmi.com.
About BXCL501
In indications other than those approved by the FDA as IGALMI™ BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist.
About
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation statements regarding the Company’s expected timing of, protocols for and data results from, trials and clinical studies involving its product candidates; potential market opportunity for BXCL501; the potential for the results from the Company’s completed, ongoing and proposed clinical trials to support regulatory approvals for its product candidates; its ongoing strategy for IGALMI; anticipated cost savings; expected cash runway and cash burn rates; the Company’s expected refinancing of its strategic financing agreements; the expected outcomes of discussions with the FDA and paths to potential sNDA approval of BXCL501; strategic options for OnkosXcel; future access to capital; and the Company’s future financial and operational results. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “when,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its ability to successfully enter into definitive documentation with its strategic financing lenders for amended terms under the financing agreements; its significant indebtedness and potential payment obligations related to such indebtedness and other contractual obligations; risks associated with the strategic reprioritization; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY II Phase 3 trial and related investigation; its dependence on the success and commercialization of IGALMI™, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; its lack of experience in marketing and selling drug products; the risk that IGALMI or the Company’s product candidates may not be accepted by physicians or the medical community in general; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on
Contact Information
Corporate
1.203.494.7062
ekopp@bioxceltherapeutics.com
Investor Relations
1.475.355.8462
bdoyle@bioxceltherapeutics.com
Media
1.858.717.2310
David.schull@russopartnersllc.com
1.646.942.5630
Scott.stachowiak@russopartnersllc.com
Source:
IGALMI™ is a trademark of
BT BIOXCEL THERAPEUTICS is a registered trademark of
All other trademarks are the properties of their respective owners.
Copyright © 2023, BioXcel Therapeutics, Inc. All rights reserved.
Statements of Operations | |||||||||||||||
(Unaudited, in thousands, except per share amounts) | |||||||||||||||
Three months ended | Nine months ended | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
Revenues | |||||||||||||||
Product revenues | $ | 341 | $ | 137 | $ | 1,004 | $ | 137 | |||||||
Operating expenses | |||||||||||||||
Cost of goods sold | 512 | 11 | 546 | 11 | |||||||||||
Research and development | 19,619 | 22,062 | 74,392 | 58,780 | |||||||||||
Selling, general and administrative | 24,344 | 17,054 | 73,810 | 48,097 | |||||||||||
Restructuring costs | 4,163 | - | 4,163 | - | |||||||||||
Total operating expenses | 48,638 | 39,127 | 152,911 | 106,888 | |||||||||||
Loss from operations | (48,297 | ) | (38,990 | ) | (151,907 | ) | (106,751 | ) | |||||||
Other (income) expense | |||||||||||||||
Interest expense, net | 2,184 | 2,877 | 5,176 | 4,251 | |||||||||||
Other expense (income), net | 5 | (62 | ) | (286 | ) | (53 | ) | ||||||||
Net loss and comprehensive loss | $ | (50,486 | ) | $ | (41,805 | ) | $ | (156,797 | ) | $ | (110,949 | ) | |||
Net loss per share - basic and diluted | $ | (1.72 | ) | $ | (1.49 | ) | $ | (5.40 | ) | $ | (3.96 | ) | |||
Weighted average shares outstanding - basic and diluted | 29,268 | 28,022 | 29,026 | 27,997 | |||||||||||
Condensed Balance Sheets | |||||||||||||||
(Unaudited, in thousands) | |||||||||||||||
2023 | 2022 | ||||||||||||||
Cash and cash equivalents | $ | 89,961 | $ | 193,725 | |||||||||||
Working capital | $ | 59,330 | $ | 169,970 | |||||||||||
Total assets | $ | 100,449 | $ | 205,853 | |||||||||||
Long-term liabilities | $ | 101,649 | $ | 96,180 | |||||||||||
Total liabilities | $ | 141,057 | $ | 129,078 | |||||||||||
Total stockholders' (deficit) equity | $ | (40,608 | ) | $ | 76,775 |
Source:
2023 GlobeNewswire, Inc., source